Presentations: Leipzig Interventional Course – interdisciplinary global platform for endovascular interventions

Room 1 - Main Arena 1

22 events

Tuesday, January 24th: 8:00 - 9:30, Room 1 - Main Arena 1

SYMPOSIUM: New evidence for broadened indications using new generation stents in fempop obstructions

supported with an educational grant from Abbott Vascular

Moderator:

Dierk Scheinert

Panel:

Andrej Schmidt, Marcus Treitl, Miguel Montero-Baker, Konstantinos Katsanos, Luis Mariano Palena, Yann Gouëffic
1. 08:00 - 08:07
  
  Overview of all available stents for use in the SFA/popliteal arteries
2. 08:07 - 08:14
  
  Stent design matters – results from a single operator registry
3. 08:14 - 08:49
  
  Live case transmission from Leipzig
4. 08:49 - 08:56
  
  Advancing medical care in highly diseased patients – the US experience
5. 08:56 - 09:03
  
  SUPERFAST – a prospective CTOs registry propensity matched with a historical SNS cohort
6. 09:03 - 09:10
  
  The PRESTO technique for precise placement of the SUPERA in the SFA ostium and SUPERSUB update
7. 09:10 - 09:17
  
  CFA stenting experiences to date and insights into the CFA SUPERA study
8. 09:17 - 09:30
  
  Live case transmission from Dendermonde
Tuesday, January 24th: 9:30 - 11:00, Room 1 - Main Arena 1

Drug-eluting devices for prevention of restenosis – the new standard for femoropopliteal interventions in claudicants

Moderator:

Dierk Scheinert, Ramon Varcoe

Panel:

John Laird, Marc Bosiers, Lawrence Garcia, Erich Minar
1. 09:30 - 09:50
  
  DCB CLINICAL TRIAL UPDATE
2. 09:30 - 09:35
  
  Update on 12-month results of the European and US Illumenate RCTs
3. 09:35 - 09:40
  
  2-year results of the AcoArt1 – RCT for the use of the Orchid ® DCB in femoropopliteal artery disease
4. 09:40 - 09:45
  
  Current status of drug coated balloon treatment in the SFA: What do the 3 year outcomes from the IN.PACT SFA RCT tell us?
5. 09:45 - 09:50
  
  A real-world look at treatment effects of IN.PACT Admiral DCB: 12-month results from the IN.PACT Global Study full clinical cohort
6. 09:50 - 09:55
  
  FIRST TIME DATA RELEASE: 6-month results of the RANGER RCT – diabetic subgroup
7. 09:55 - 10:00
  
  FIRST TIME DATA RELEASE: 12-month results from the MDT-2113 SFA Japan trial – DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA
8. 10:00 - 10:05
  
  FIRST TIME DATA RELEASE: DCB: 12-month results of the CONSEQUENT RCT
9. 10:05 - 10:10
  
  FIRST TIME DATA RELEASE: The Lutonix EU Long lesion study
10. 10:10 - 10:15
  
  FIRST TIME DATA RELEASE: 12-month results of the Illumenate Global Study
11. 10:15 - 10:20
  
  FIRST TIME DATA RELEASE: Catheter-mediated deep adventitial microinfusion of dexamethasone for restenosis prevention in femoropopliteal arteries – 12-month results of the DANCE trial
12. 10:20 - 10:25
  
  FIRST TIME DATA RELEASE: 2-year results of the REAL-PTX randomised clinical trial comparing Zilver PTX vs. DCB treatment in femoropopliteal lesions
13. 10:25 - 10:30
  
  2-year data from the MAJESTIC DES trial for treatment of femoropopliteal disease
14. 10:30 - 10:35
  
  DCB + stent in the SFA: 12-month results of the Biolux4ever trial
15. 10:35 - 10:40
  
  Patterns of restenosis: a core lab driven assessment of SFA restenosis a potential shift to unify various trials
16. 10:40 - 10:47
  
  Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial
17. 10:47 - 10:54
  
  Are drug-eluting devices the new standard for femoropopliteal interventions in claudication?
18. 10:54 - 11:00
  
  Discussion
Tuesday, January 24th: 11:00 - 12:30, Room 1 - Main Arena 1

SYMPOSIUM: Drug elution in the SFA: Leave the right thing behind. Debating evidence to provide an answer

supported with a restricted educational grant from Cook Medical

Moderator:

Michael Dake

Panel:

Erwin Blessing, Aloke Finn, Iris Baumgartner
1. 11:00 - 11:05
  
  Introduction
2. 11:05 - 11:15
  
  Why and how to prep the vessel
3. 11:15 - 11:35
  
  Live case transmission from Dendermonde
4. 11:35 - 11:45
  
  Understanding restenosis in the SFA
5. 11:45 - 11:55
  
  The importance of scientific evidence
6. 11:55 - 12:15
  
  Live case transmission from Münster
7. 12:15 - 12:20
  
  Summing up on symposium
8. 12:20 - 12:30
  
  Discussion and debate
Tuesday, January 24th: 12:30 - 13:30, Room 1 - Main Arena 1

Lunch
Tuesday, January 24th: 13:30 - 15:00, Room 1 - Main Arena 1

SYMPOSIUM: Past, present, future: How DCB is enabling treatment of more complex femoropopliteal artery lesions

supported with an educational grant from Medtronic

Moderator:

Dierk Scheinert, Krishna Rocha-Singh

Panel:

Thomas Zeller, John Laird, Osamu Iida, Juan Fernando Granada Solis
1. 13:30 - 13:35
  
  Introduction
2. 13:35 - 13:45
  
  Evolution of DCB technology
3. 13:45 - 13:48
  
  Discussion
4. 13:48 - 14:08
  
  Live case transmission from Leipzig
5. 14:08 - 14:18
  
  IN.PACT drug-coated balloon: Consistent clinical outcomes across patient populations
6. 14:18 - 14:21
  
  Discussion
7. 14:21 - 14:31
  
  Gain lumen, maintain patency: The power of adjunctive therapy with directional atherectomy and DCB
8. 14:31 - 14:34
  
  Discussion
9. 14:34 - 14:55
  
  Live case transmission from New York
10. 14:55 - 15:00
  
  Conclusion and summary
Tuesday, January 24th: 15:00 - 16:30, Room 1 - Main Arena 1

SYMPOSIUM: Redefining SFA treatment in a drug-eluting world

supported with an educational grant from Boston Scientific

Moderator:

Dierk Scheinert, Iris Baumgartner

Panel:

Gunnar Tepe, Thomas Zeller, Konstantinos Katsanos
1. 15:00 - 15:03
  
  Introduction and learning objectives
2. 15:03 - 15:15
  
  Drug coated balloons – for all or some?
3. 15:15 - 15:27
  
  Eluvia drug eluting stent: A platform for success?
4. 15:27 - 16:01
  
  Live case transmission from Leipzig
5. 16:01 - 16:13
  
  Getting to answers with clinical trials: being bold
6. 16:13 - 16:25
  
  Why you should care about health economics in PAD: Funding meaningful innovation
7. 16:25 - 16:30
  
  Close and take home learnings
Tuesday, January 24th: 16:30 - 18:00, Room 1 - Main Arena 1

THE LAST FRONTIERS: New concepts for calcified lesions

Moderator:

Chris Metzger, Hiroyoshi Yokoi

Panel:

Marcus Thieme, Gunnar Tepe, Lieven Maene, Thomas Heller, James McKinsey
1. 16:30 - 16:37
  
  Patterns of calcification: intimal vs. medial and differences below and above the knee
2. 16:37 - 16:44
  
  The Shockwave lithoplasty concept – latest results
3. 16:44 - 17:04
  
  Live case transmission from Leipzig
4. 17:04 - 17:11
  
  Importance of thorough vessel preparation followed by anti-restenotic therapy: an update from the DEFINITIVE AR study
5. 17:11 - 17:16
  
  Treatment of challenging calcified lesions with the next generation. Phoenix atherectomy system
6. 17:16 - 17:21
  
  Recorded case
7. 17:21 - 17:28
  
  10 steps to percutaneous bypass of extra long, complex SFA occlusions
8. 17:28 - 17:35
  
  FIRST TIME DATA RELEASE: The DETOUR trial: Six-month outcomes of percutaneous bypass in long segment femoral-popliteal occlusions
9. 17:35 - 17:55
  
  Live case transmission from New York
10. 17:55 - 18:00
  
  Discussion
Wednesday, January 25th: 8:00 - 9:30, Room 1 - Main Arena 1

Optimising outcome of BTK interventions in CLI – Current approaches and future outlook

Moderator:

Dierk Scheinert, Jihad Mustapha

Panel:

Peter Schneider, Ramon Varcoe, Juan Fernando Granada Solis, Osamu Iida, Frank Vermassen, Mohammad AlTwalah
1. 08:00 - 08:10
  
  Live case transmission from Leipzig – part I
2. 08:10 - 08:15
  
  Prognostic impact of revascularisation in poor-risk patients with critical limb ischaemia: The PRIORITY registry
3. 08:15 - 08:21
  
  What have we learned from past DCB BTK studies: Technology, clinical study design, and patient management
4. 08:21 - 08:27
  
  Does paclitaxel interfere with wound healing?
5. 08:27 - 08:33
  
  How do I treat BTK/CLI with DCB: Past experience and a new beginning
6. 08:33 - 08:39
  
  Drug eluting devices: Why paclitaxel works above the knee and sirolimus below the knee, is the stent or the drug?
7. 08:39 - 08:43
  
  The clinical rationale: Why endpoints for CLI trials should be evaluated at 6 months instead of 1 year
8. 08:43 - 08:49
  
  Alternative methods of drug delivery: The LIMBO trial
9. 08:49 - 09:05
  
  Live case transmission from Leipzig – part II
10. 09:05 - 09:10
  
  Towards optimised BTK results by preventing recoil and sealing dissections – TOBA BTK
11. 09:10 - 09:15
  
  Bioabsorbable scaffolds in BTK arteries: 24-month results from ABSORB BTK
12. 09:15 - 09:20
  
  1-year results in real world patients with ABSORB BTK
13. 09:20 - 09:25
  
  Dealing with calcification in BTK arteries – is lithoplasty the answer?
14. 09:25 - 09:30
  
  Percutanoues deep venous arteriolisation for no-option CLI – 1-year results
Wednesday, January 25th: 9:30 - 11:00, Room 1 - Main Arena 1

SYMPOSIUM: Leading DCB era in China – Current evidence and practice

supported with an educational grant from Acotec

Moderator:

Wei Guo

Panel:

Dierk Scheinert, Weiguo Fu, Zhong Chen, Zhidong Ye, Francesco Liistro
1. 09:30 - 09:39
  
  DCB is changing the treatment paradigm of femoral-popliteal lesions in China
2. 09:39 - 09:48
  
  Orchid DCB in Leipzig – real world experience
3. 09:48 - 09:57
  
  Orchid DCB brings new life to a ISR patient – Story behind 31 month patency
4. 09:57 - 10:06
  
  How did DCB change my treatment principle in femoral-popliteal lesions
5. 10:06 - 10:15
  
  Long DCB in long lesion – benefits for lesions beyond 150mm
6. 10:15 - 10:24
  
  Atherectomy plus DCB: China experience
7. 10:24 - 10:33
  
  DCB in BTK: Preliminary result from Acoart BTK study
8. 10:33 - 10:50
  
  Live case transmission from Leipzig
9. 10:50 - 11:00
  
  Discussion and summary
Wednesday, January 25th: 11:00 - 12:30, Room 1 - Main Arena 1

SYMPOSIUM: Proven long-term outcomes for complex femoropopliteal lesions

supported with an educational grant from Gore & Associates

Moderator:

Giovanni Torsello

Panel:

Peter Soukas, Takao Ohki, Michel Reijnen, Jorge Fernández Noya
1. 11:00 - 11:05
  
  The endoluminal bypass – What have we learnt so far
2. 11:05 - 11:20
  
  Live case transmission from Münster
3. 11:20 - 11:30
  
  How to achieve good results with Gore Viabahn for treating complex femoropopliteal occlusive disease: Results from the Japanese IDE trial
4. 11:30 - 11:35
  
  Discussion
5. 11:35 - 11:55
  
  Live case transmission from Leipzig
6. 11:55 - 12:05
  
  Dealing with edge stenosis and outcomes of failed endografts
7. 12:05 - 12:10
  
  Discussion
8. 12:10 - 12:20
  
  Best practices in the treatment of TASC C & D lesion of femoro-popliteal district in CLI patient 4-year results
9. 12:20 - 12:30
  
  Discussion and conclusion
Wednesday, January 25th: 12:30 - 13:30, Room 1 - Main Arena 1

Lunch
Wednesday, January 25th: 13:30 - 15:00, Room 1 - Main Arena 1

SYMPOSIUM: Lutonix® Drug Coated Balloon – Evidence in SFA, BTK, and AV

supported with an educational grant from C. R. BARD

Moderator:

Dierk Scheinert

Panel:

Aloke Finn, Michael Lichtenberg, Antonio Micari, Scott O. Trerotola
1. 13:30 - 13:35
  
  Introduction
2. 13:35 - 13:43
  
  A study of downstream events of the two leading DCBs on the market
3. 13:43 - 13:50
  
  Lutonix® efficacy in BTK: Results of Lutonix® drug-coated balloons angioplasty in below the knee arteries in critical limb ischemia patients
4. 13:50 - 14:00
  
  Clinical benefits at 12-month from the Lutonix EU long lesion study
5. 14:00 - 14:20
  
  Live case transmission from Leipzig
6. 14:20 - 14:27
  
  An interim look at the Lutonix®DCB Global Real World BTK registry - 6-month outcomes
7. 14:27 - 14:35
  
  A first look at the LUTONIX® Catheter IDE clinical trial demographics, lesion, and procedural variables in AV fistula
8. 14:35 - 14:45
  
  Lutonix® efficacy in AV: On-going PAVE study
9. 14:45 - 15:00
  
  Conclusion and FAQ
Wednesday, January 25th: 15:00 - 16:30, Room 1 - Main Arena 1

VIVA@LINC: DCBs – Where we are and where do we need to be?

Moderator:

Michael Dake

Panel:

Krishna Rocha-Singh, Lawrence Garcia, Saher Sabri, Peter Schneider
1. 15:00 - 15:05
  
  Announcement of the winners of the Vascular Career Award 2016
2. 15:05 - 15:13
  
  DCB Potential beyond the selected SFA lesion types studied in trials to date: What we know about the real world
3. 15:13 - 15:39
  
  Live case transmission from Columbus
4. 15:39 - 15:47
  
  Current views on vessel prep prior to DCB – pre-dil, atherectomy, etc., what we’ve learned
5. 15:47 - 15:55
  
  Current status of DCB experience with non-femoropopliteal applications (dialysis, tibial, venous, etc.)
6. 15:55 - 16:22
  
  Live case transmission from Columbus
7. 16:22 - 16:30
  
  DCB and restenosis; who fails and why: What we do about it now and what the future holds
Wednesday, January 25th: 16:30 - 18:00, Room 1 - Main Arena 1

New concepts for complex femoropopliteal disease

Moderator:

Marc Bosiers, Takao Ohki

Panel:

Sabine Steiner, Dong-Hoon Choi, Ralf Langhoff, Antonio Micari, James McKinsey, Osamu Iida
1. 16:30 - 16:36
  
  2-year outcomes from the DEB-SFA-Long Study
2. 16:36 - 16:42
  
  Tack-optimised angioplasty (TOBA) – Update on latest data and current projects
3. 16:42 - 16:48
  
  6-month results of the LOCOMOTIVE registry investigating spot stenting in the femoropopliteal tract
4. 16:48 - 16:54
  
  The MIMICS-2 IDE study: interim update on BioMimics 3D in US, Japan, and Europe
5. 16:54 - 17:14
  
  Live case transmission from Leipzig
6. 17:14 - 17:20
  
  FIRST TIME DATA RELEASE: 2-year results of the VIABAHN Japan IDE trial for complex SFA lesions
7. 17:20 - 17:26
  
  FIRST TIME DATA RELEASE: 3-year results of ZEPHYR (ZilvEr PTX for tHe Femoral ArterY and Proximal Popliteal ArteRy) study
8. 17:26 - 17:48
  
  Live case transmission from Columbus
9. 17:48 - 17:54
  
  Comparing endoluminal bypass to open fempop bypasses: Final 1-year results of the SUPERB trial
10. 17:54 - 18:00
  
  Surgical bypass vs. ZilverPTX stent for long SFA lesions: Interim results of the Zilverpass trial
Thursday, January 26th: 8:00 - 9:30, Room 1 - Main Arena 1

THE LAST FRONTIERS: Complex tibial and below-the-ankle interventions

Moderator:

Jihad Mustapha, Roberto Ferraresi

Panel:

Frank Vermassen, Michael Edmonds, Keisuke Hirano, Steven Kum, Sigrid Nikol
1. 08:00 - 08:25
  
  Live case transmission from Leipzig
2. 08:25 - 08:32
  
  Angiosome revascularisation strategies in real world practice: how much difference does it make?
3. 08:32 - 08:39
  
  Retrograde tibial puncture has changed the algorithm for crossing tibial lesions in CLI: How and when to do It?
4. 08:39 - 08:46
  
  A systematic review of results with the retrograde tibial approach
5. 08:46 - 09:11
  
  Live case transmission from Abano Terme
6. 09:11 - 09:18
  
  When is below-the-ankle angioplasty indicated and how to introduce it into your practice
7. 09:18 - 09:25
  
  Aggressive below-the-ankle intervention: Its effect on long term outcome
8. 09:25 - 09:30
  
  Discussion and conclusion
Thursday, January 26th: 9:30 - 11:00, Room 1 - Main Arena 1

SYMPOSIUM: Built on evidence: Stellarex DCB technology and clinical program

supported with an educational grant from Spectranetics

Moderator:

Sean Lyden

Panel:

Marianne Brodmann, Stephan Duda, Henrik Schröder, Giovanni Torsello, Michael Lichtenberg
1. 09:30 - 09:38
  
  4 trials/1.000+ patients: results from the ILLUMENATE SFA program
2. 09:38 - 09:58
  
  Live case transmission from Bad Krozingen
3. 09:58 - 10:06
  
  Stellarex evidence in diabetics
4. 10:06 - 10:12
  
  Stellarex evidence in females
5. 10:12 - 10:18
  
  Role of vessel preparation in contemporary DCB practice
6. 10:18 - 10:55
  
  Live case transmission from Leipzig
7. 10:55 - 11:00
  
  Discussion and conclusion
Thursday, January 26th: 11:00 - 12:30, Room 1 - Main Arena 1

Glimpse into the future: New treatment approaches and technologies for peripheral arterial disease

Moderator:

William Gray, Marianne Brodmann

Panel:

Andrew Holden, George Adams, Bob Smouse, Stephan Duda, Andrej Erglis
1. 11:00 - 11:06
  
  Clinical outcomes and magnetic resonance angiography assessment of a new dual component vascular stent
2. 11:06 - 11:12
  
  Design principles of the BioMimics 3D stent and why it's ideal for fempop intervention
3. 11:12 - 11:17
  
  Real world experience with BioMimics 3D, the swirling flow stent
4. 11:17 - 11:36
  
  Live case transmission from Bad Krozingen
5. 11:36 - 11:41
  
  FIRST TIME DATA RELEASE: Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of femoropopliteal lesions
6. 11:41 - 11:47
  
  Direct micropuncture mediated deep adventitial drug delivery – New insights from the DANCE project and future prospects
7. 11:47 - 11:53
  
  Percutaneous bypass with the DETOUR procedure: Using the femoral vein as a natural conduit ... In situ with a twist!
8. 11:53 - 12:18
  
  Live case transmission from Münster
9. 12:18 - 12:24
  
  New evidence review for OCT guided atherectomy: Long term patency, in-stent restenosis, and zero contrast/fluoroscopy in CKD patients
10. 12:24 - 12:30
  
  Future of OCT guided technologies for PAD: True lumen measurement, BTK platform, and calcium therapies
Thursday, January 26th: 12:30 - 13:25, Room 1 - Main Arena 1

LUNCH SYMPOSIUM: Live case with Dr. Andrej Schmidt: Sophisticated CLI access and crossing techniques

supported with a restricted educational grant from Cook Medical

Moderator:

Craig Walker

Panel:

Roberto Ferraresi, Flavio Airoldi, Miguel Montero-Baker

live with:

Andrej Schmidt
Thursday, January 26th: 13:30 - 15:00, Room 1 - Main Arena 1

Treatment of complex aortoiliac disease: Latest techniques and results

Moderator:

Hans Krankenberg, Patrick Peeters

Panel:

Peter Goverde, Frank Vermassen, Gustavo Oderich, Peter Soukas, Patrice Mwipatayi
1. 13:30 - 13:55
  
  Live case transmission from Leipzig
2. 13:55 - 14:02
  
  Outcomes of polytetrafluoroethylene-covered stent in the primary treatment of severe iliac artery obstructive lesions
3. 14:02 - 14:09
  
  Endovascular treatment of severe TASC C and D external iliac artery occlusive disease
4. 14:09 - 14:16
  
  Final results of the BOLSTER study: A prospective, multicenter study of a balloon-expandable ePTFE-covered stent for obstructive lesions in the iliac artery
5. 14:16 - 14:23
  
  Covered endovascular reconstruction of the aortic bifurcation (CERAB) as treatment of extensive aortoiliac occlusive disease: 3-year results
6. 14:23 - 14:48
  
  Live case transmission from Bad Krozingen
7. 14:48 - 15:00
  
  Discussion
Thursday, January 26th: 15:00 - 16:30, Room 1 - Main Arena 1

Challenges and new concepts in hemodialysis access and upper extremity interventions

Moderator:

Andrew Holden, Stephan Duda

Panel:

Konstantinos Katsanos, Daniela Branzan, Roberto Ferraresi
1. 15:00 - 15:07
  
  Strategy and technical tips in treating AV fistulas
2. 15:07 - 15:22
  
  Review of clinical evidence: The role of DCB for the treatment of failing dialysis access stenosis
3. 15:22 - 15:27
  
  FIRST TIME DATA RELEASE: 6-month results of the Lutonix US IDE trial for treatment of AV-fistula obstructions in HD patients
4. 15:27 - 15:34
  
  Technical aspects for treating AV fistulae with IN.PACT DCB
5. 15:34 - 15:39
  
  Endovascular treatment for central venous obstruction in hemodialysis patients
6. 15:39 - 16:06
  
  Live case transmission from Münster
7. 16:06 - 16:13
  
  Shifting the paradigm for dialysis access: The latest everlinQ endoAVF clinical experience and technology evolution – T. Steinke
8. 16:13 - 16:20
  
  What is the true cause of critical hand ischaemia? Results in a large cohort of hemodialysis patients
9. 16:20 - 16:27
  
  Thrombolytic therapy of distal upper extremity occlusions (hypothenar hammer syndrome): A therapeutic option for a rare disease
10. 16:27 - 16:30
  
  Discussion
Thursday, January 26th: 16:30 - 18:00, Room 1 - Main Arena 1

THE LAST FRONTIERS: Interventional treatment of common femoral and popliteal artery disease

Moderator:

Lawrence Garcia, Marc Bosiers

Panel:

Bob Smouse, Sven Seifert, Torsten Fuß, Yann Gouëffic, Chris Metzger, Wei Liang
1. 16:30 - 16:37
  
  The common femoral artery – an anatomical region still reserved for treatment by the surgeons?
2. 16:37 - 16:44
  
  Stenting of the common femoral artery for atherosclerotic lesions: is it feasible and how and when we do it
3. 16:44 - 17:08
  
  Live case transmission from Bad Krozingen
4. 17:08 - 17:15
  
  A randomized comparison of endovascular versus surgery treatment of common femoral artery disease: Results from the TECCO trial
5. 17:15 - 17:22
  
  First experiences in the VMI-CFA study: investigating the Supera stent in the common femoral artery. Is the Supera a valuable alternative for common femoral endarterectomy?
6. 17:22 - 17:46
  
  Live case transmission from Leipzig
7. 17:46 - 17:53
  
  DCB for popliteal artery stenosis: The IN.PACT Flexion trial
8. 17:53 - 18:00
  
  Directional atherectomy plus DCB versus DCB alone for isolated lesions of the popliteal artery
Friday, January 27th: 9:00 - 12:30, Room 1 - Main Arena 1

Critical issues and pioneering solutions in aortic endografting

Moderator:

Martin Malina, Marc van Sambeek

Panel:

Eric Verhoeven, Thomas Larzon, Piotr Kasprzak, Karin Brachmann
1. 09:00 - 09:40
  
  Live case transmission from Münster
2. 09:40 - 09:47
  
  Endovascular and hybrid approach in the treatment of aberrant subclavian artery and its aneurysm
3. 09:47 - 09:54
  
  In patients with a ruptured it is justified to push the borders of anatomical suitability
4. 09:54 - 10:01
  
  Infected stentgrafts and aneurysms of the aorta: Endovascular repair offers lower early mortality and similar long term results as open repair
5. 10:01 - 10:08
  
  Infective complications after TEVAR: Incidence and treatment options
6. 10:08 - 10:45
  
  Live case transmission from Leipzig
7. 10:45 - 10:52
  
  Association between polycystic kidney disease and aortic aneurysm, presentation of case report and literature review
8. 10:52 - 10:59
  
  Impact of iliac arteries anatomy on the outcome of FB – EVAR
9. 10:59 - 11:06
  
  Retroperitioneal access to target arteries: a bail-out procedure when prograde branch catheterisation does not work for F/B EVAR
10. 11:06 - 11:46
  
  Live case transmission from Münster
11. 11:46 - 12:30
  
  Discussion and conclusion

Notice

LINC 2017 programme

Room 1 - Main Arena 1

SYMPOSIUM: New evidence for broadened indications using new generation stents in fempop obstructions

Overview of all available stents for use in the SFA/popliteal arteries

Stent design matters – results from a single operator registry

Live case transmission from Leipzig

Advancing medical care in highly diseased patients – the US experience

SUPERFAST – a prospective CTOs registry propensity matched with a historical SNS cohort

The PRESTO technique for precise placement of the SUPERA in the SFA ostium and SUPERSUB update

CFA stenting experiences to date and insights into the CFA SUPERA study

Live case transmission from Dendermonde

Drug-eluting devices for prevention of restenosis – the new standard for femoropopliteal interventions in claudicants

DCB CLINICAL TRIAL UPDATE

Update on 12-month results of the European and US Illumenate RCTs

2-year results of the AcoArt1 – RCT for the use of the Orchid ® DCB in femoropopliteal artery disease

Current status of drug coated balloon treatment in the SFA: What do the 3 year outcomes from the IN.PACT SFA RCT tell us?

A real-world look at treatment effects of IN.PACT Admiral DCB: 12-month results from the IN.PACT Global Study full clinical cohort

FIRST TIME DATA RELEASE: 6-month results of the RANGER RCT – diabetic subgroup

FIRST TIME DATA RELEASE: 12-month results from the MDT-2113 SFA Japan trial – DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA

FIRST TIME DATA RELEASE: DCB: 12-month results of the CONSEQUENT RCT

FIRST TIME DATA RELEASE: The Lutonix EU Long lesion study

FIRST TIME DATA RELEASE: 12-month results of the Illumenate Global Study

FIRST TIME DATA RELEASE: Catheter-mediated deep adventitial microinfusion of dexamethasone for restenosis prevention in femoropopliteal arteries – 12-month results of the DANCE trial

FIRST TIME DATA RELEASE: 2-year results of the REAL-PTX randomised clinical trial comparing Zilver PTX vs. DCB treatment in femoropopliteal lesions

2-year data from the MAJESTIC DES trial for treatment of femoropopliteal disease

DCB + stent in the SFA: 12-month results of the Biolux4ever trial

Patterns of restenosis: a core lab driven assessment of SFA restenosis a potential shift to unify various trials

Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial

Are drug-eluting devices the new standard for femoropopliteal interventions in claudication?

Discussion

SYMPOSIUM: Drug elution in the SFA: Leave the right thing behind. Debating evidence to provide an answer

Introduction

Why and how to prep the vessel

Live case transmission from Dendermonde

Understanding restenosis in the SFA

The importance of scientific evidence

Live case transmission from Münster

Summing up on symposium

Discussion and debate

Lunch

SYMPOSIUM: Past, present, future: How DCB is enabling treatment of more complex femoropopliteal artery lesions

Introduction

Evolution of DCB technology

Discussion

Live case transmission from Leipzig

IN.PACT drug-coated balloon: Consistent clinical outcomes across patient populations

Discussion

Gain lumen, maintain patency: The power of adjunctive therapy with directional atherectomy and DCB

Discussion

Live case transmission from New York

Conclusion and summary

SYMPOSIUM: Redefining SFA treatment in a drug-eluting world

Introduction and learning objectives

Drug coated balloons – for all or some?

Eluvia drug eluting stent: A platform for success?

Live case transmission from Leipzig

Getting to answers with clinical trials: being bold

Why you should care about health economics in PAD: Funding meaningful innovation

Close and take home learnings

THE LAST FRONTIERS: New concepts for calcified lesions

Patterns of calcification: intimal vs. medial and differences below and above the knee

The Shockwave lithoplasty concept – latest results

Live case transmission from Leipzig

Importance of thorough vessel preparation followed by anti-restenotic therapy: an update from the DEFINITIVE AR study

Treatment of challenging calcified lesions with the next generation. Phoenix atherectomy system

Recorded case

10 steps to percutaneous bypass of extra long, complex SFA occlusions

FIRST TIME DATA RELEASE: The DETOUR trial: Six-month outcomes of percutaneous bypass in long segment femoral-popliteal occlusions

Live case transmission from New York

Discussion

Optimising outcome of BTK interventions in CLI – Current approaches and future outlook

Live case transmission from Leipzig – part I

Prognostic impact of revascularisation in poor-risk patients with critical limb ischaemia: The PRIORITY registry

What have we learned from past DCB BTK studies: Technology, clinical study design, and patient management

Does paclitaxel interfere with wound healing?

How do I treat BTK/CLI with DCB: Past experience and a new beginning

Drug eluting devices: Why paclitaxel works above the knee and sirolimus below the knee, is the stent or the drug?

The clinical rationale: Why endpoints for CLI trials should be evaluated at 6 months instead of 1 year

Alternative methods of drug delivery: The LIMBO trial